85 related articles for article (PubMed ID: 17463029)
1. Two-stage designs applying methods differing in costs.
Goll A; Bauer P
Bioinformatics; 2007 Jun; 23(12):1519-26. PubMed ID: 17463029
[TBL] [Abstract][Full Text] [Related]
2. Optimized multi-stage designs controlling the false discovery or the family-wise error rate.
Zehetmayer S; Bauer P; Posch M
Stat Med; 2008 Sep; 27(21):4145-60. PubMed ID: 18444249
[TBL] [Abstract][Full Text] [Related]
3. Two-stage designs for experiments with a large number of hypotheses.
Zehetmayer S; Bauer P; Posch M
Bioinformatics; 2005 Oct; 21(19):3771-7. PubMed ID: 16091414
[TBL] [Abstract][Full Text] [Related]
4. Optimization of two-stage genetic designs where data are combined using an accurate and efficient approximation for Pearson's statistic.
Bukszár J; van den Oord EJ
Biometrics; 2006 Dec; 62(4):1132-7. PubMed ID: 17156288
[TBL] [Abstract][Full Text] [Related]
5. Including sampling and phenotyping costs into the optimization of two stage designs for genomewide association studies.
Müller HH; Pahl R; Schäfer H
Genet Epidemiol; 2007 Dec; 31(8):844-52. PubMed ID: 17549751
[TBL] [Abstract][Full Text] [Related]
6. Adaptive two-stage analysis of genetic association in case-control designs.
Zheng G; Song K; Elston RC
Hum Hered; 2007; 63(3-4):175-86. PubMed ID: 17310127
[TBL] [Abstract][Full Text] [Related]
7. Balanced two-stage designs for phase II clinical trials.
Ye F; Shyr Y
Clin Trials; 2007; 4(5):514-24. PubMed ID: 17942467
[TBL] [Abstract][Full Text] [Related]
8. Optimal robust two-stage designs for genome-wide association studies.
Nguyen TT; Pahl R; Schäfer H
Ann Hum Genet; 2009 Nov; 73(Pt 6):638-51. PubMed ID: 19839987
[TBL] [Abstract][Full Text] [Related]
9. Detailed analysis of the relative power of direct and indirect association studies and the implications for their interpretation.
Moskvina V; O'Donovan MC
Hum Hered; 2007; 64(1):63-73. PubMed ID: 17483598
[TBL] [Abstract][Full Text] [Related]
10. Optimal designs for two-stage genome-wide association studies.
Skol AD; Scott LJ; Abecasis GR; Boehnke M
Genet Epidemiol; 2007 Nov; 31(7):776-88. PubMed ID: 17549752
[TBL] [Abstract][Full Text] [Related]
11. Optimal multistage designs--a general framework for efficient genome-wide association studies.
Pahl R; Schäfer H; Müller HH
Biostatistics; 2009 Apr; 10(2):297-309. PubMed ID: 19075295
[TBL] [Abstract][Full Text] [Related]
12. Computational methods for the comparative quantification of proteins in label-free LCn-MS experiments.
Wong JW; Sullivan MJ; Cagney G
Brief Bioinform; 2008 Mar; 9(2):156-65. PubMed ID: 17905794
[TBL] [Abstract][Full Text] [Related]
13. Optimal and minimax three-stage designs for phase II oncology clinical trials.
Chen K; Shan M
Contemp Clin Trials; 2008 Jan; 29(1):32-41. PubMed ID: 17544337
[TBL] [Abstract][Full Text] [Related]
14. Adaptive designs: looking for a needle in the haystack-a new challenge in medical research.
Bauer P
Stat Med; 2008 May; 27(10):1565-80. PubMed ID: 17935261
[TBL] [Abstract][Full Text] [Related]
15. Optimal designs of two-stage studies for estimation of sensitivity, specificity and positive predictive value.
McNamee R
Stat Med; 2002 Dec; 21(23):3609-25. PubMed ID: 12436459
[TBL] [Abstract][Full Text] [Related]
16. Statistical identification of differentially labeled peptides from liquid chromatography tandem mass spectrometry.
Cho H; Smalley DM; Theodorescu D; Ley K; Lee JK
Proteomics; 2007 Oct; 7(20):3681-92. PubMed ID: 17879999
[TBL] [Abstract][Full Text] [Related]
17. Improving the success rate of proteome analysis by modeling protein-abundance distributions and experimental designs.
Eriksson J; Fenyö D
Nat Biotechnol; 2007 Jun; 25(6):651-5. PubMed ID: 17557102
[TBL] [Abstract][Full Text] [Related]
18. Increasing the mass accuracy of high-resolution LC-MS data using background ions: a case study on the LTQ-Orbitrap.
Scheltema RA; Kamleh A; Wildridge D; Ebikeme C; Watson DG; Barrett MP; Jansen RC; Breitling R
Proteomics; 2008 Nov; 8(22):4647-56. PubMed ID: 18937253
[TBL] [Abstract][Full Text] [Related]
19. A Bayesian segmentation approach to ascertain copy number variations at the population level.
Wu LY; Chipman HA; Bull SB; Briollais L; Wang K
Bioinformatics; 2009 Jul; 25(13):1669-79. PubMed ID: 19389735
[TBL] [Abstract][Full Text] [Related]
20. Two-stage designs for dose-finding trials with a biologic endpoint using stepwise tests.
Polley MY; Cheung YK
Biometrics; 2008 Mar; 64(1):232-41. PubMed ID: 17573866
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
